WO2005099681A1 - 分岐鎖アミノ酸を含有する錠剤およびその製造方法 - Google Patents
分岐鎖アミノ酸を含有する錠剤およびその製造方法 Download PDFInfo
- Publication number
- WO2005099681A1 WO2005099681A1 PCT/JP2005/007203 JP2005007203W WO2005099681A1 WO 2005099681 A1 WO2005099681 A1 WO 2005099681A1 JP 2005007203 W JP2005007203 W JP 2005007203W WO 2005099681 A1 WO2005099681 A1 WO 2005099681A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablet
- chain amino
- amino acid
- branched
- compression molding
- Prior art date
Links
- 150000005693 branched-chain amino acids Chemical class 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 29
- 238000000748 compression moulding Methods 0.000 claims abstract description 54
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 238000004519 manufacturing process Methods 0.000 claims description 33
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 21
- 239000000314 lubricant Substances 0.000 claims description 19
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 17
- 229960000310 isoleucine Drugs 0.000 claims description 17
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 17
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 17
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 17
- 239000002245 particle Substances 0.000 claims description 15
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 13
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 13
- 235000010980 cellulose Nutrition 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 238000007906 compression Methods 0.000 abstract description 8
- 230000006835 compression Effects 0.000 abstract description 8
- 239000003826 tablet Substances 0.000 description 112
- 239000008187 granular material Substances 0.000 description 14
- 229960003136 leucine Drugs 0.000 description 14
- 235000013305 food Nutrition 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 6
- -1 trenolose Chemical compound 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 239000004373 Pullulan Substances 0.000 description 5
- 229920001218 Pullulan Polymers 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 235000019423 pullulan Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229930182844 L-isoleucine Natural products 0.000 description 4
- 239000004395 L-leucine Substances 0.000 description 4
- 235000019454 L-leucine Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000845 maltitol Substances 0.000 description 4
- 235000010449 maltitol Nutrition 0.000 description 4
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 4
- 229940035436 maltitol Drugs 0.000 description 4
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000007907 direct compression Methods 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- YFAGTKDVNDHKEJ-UHFFFAOYSA-N [Si].O[N+]([O-])=O Chemical compound [Si].O[N+]([O-])=O YFAGTKDVNDHKEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- JFVXEJADITYJHK-UHFFFAOYSA-L disodium 2-(3-hydroxy-5-sulfonato-1H-indol-2-yl)-3-oxoindole-5-sulfonate Chemical compound [Na+].[Na+].Oc1c([nH]c2ccc(cc12)S([O-])(=O)=O)C1=Nc2ccc(cc2C1=O)S([O-])(=O)=O JFVXEJADITYJHK-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009477 fluid bed granulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000019223 lemon-lime Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a tablet containing a branched-chain amino acid and a method for producing the same.
- Phosphorus, leucine, isoleucine, and the like which are known as branched-chain amino acids, are effective in suppressing muscle protein degradation, preventing ischemic heart failure, protecting the liver, improving sleep disorders in patients with renal failure, improving diabetes, and the like. It is said that pharmaceutical preparations containing palin, leucine and isoleucine as active ingredients are known as pharmaceuticals for treating liver diseases.
- pharmaceutical preparations containing palin, leucine and isoleucine as active ingredients are known as pharmaceuticals for treating liver diseases.
- the nutritional and physiological functions of branched-chain amino acids have attracted attention, and drinks, foods, and the like containing these amino acids are being evaluated in the market. There are drinks, granules, tablets and the like as intake forms of the branched-chain amino acids.
- branched-chain amino acids Since the branched-chain amino acids have a unique bitter taste, it is necessary to devise the taste of these drinks, granules and tablets.
- a tablet containing a branched-chain amino acid when a tablet containing a branched-chain amino acid is to be produced, it is difficult to produce a tablet which is liable to cause compression molding failure such as adhesion of a branched-chain amino acid to a punch and die of a compression molding machine, cabbing, and statusing. Therefore, it was necessary to prevent these compression molding failures.
- Patent Literature 1 discloses that by using ratatitol as an excipient, it is possible to produce a branched-chain amino acid tablet without causing compression molding problems.
- a powdered raw material containing 0.12 to 2 parts by mass of ratatitol and 1 part by mass of a branched-chain amino acid is granulated and then dried to obtain granules, which are then used as microcrystalline cellulose as an excipient and a plant as a lubricant.
- the force is also compression molded by mixing with oils and fats.
- Patent Document 2 an amino acid such as a branched chain amino acid, one of lactose, maltose, trenolose, sorbitol, ratatitol, mannitol, xylitol and maltitol cap, and a disintegrant are disclosed.
- the resulting mixture is granulated using an aqueous binder solution and dried, and the resulting granules are compression-molded to produce amino acid-containing orally rapidly disintegrating tablets.
- Patent Document 3 discloses a chewable containing a branched-chain amino acid.
- the present invention relates to an agent for producing a granule by granulating a particle mixture containing three kinds of branched chain amino acids of isoleucine, leucine and palin as active ingredients, and producing the granules.
- the granules are coated and the coated granules are compression molded.
- reduced palatinose is a sweetener made from sugar. Reduced palatinose is suitable for obese and diabetic patients because it does not cause dental caries, is low in calories, and does not increase blood sugar. In addition, reduced palatinose is chemically stable, does not decompose under heating or acid or alkali, does not show a Maillard reaction, and has low hygroscopicity, so that it is well suited for foods and the like. Granules of reduced palatinose are known to be suitable for compression molding (for example, Patent Document 4 and the like).
- Patent Document 1 Japanese Patent Application Laid-Open No. 2001-258509
- Patent Document 2 WO 03/041698 pamphlet
- Patent Document 3 JP-A-2003-221326
- Patent Document 4 JP-A-2000-197454
- An object of the present invention is to provide a tablet containing a branched-chain amino acid, which can be produced without causing compression molding problems, and a method for producing the tablet.
- the present invention relates to the following (1) to (15).
- a tablet containing a branched-chain amino acid and reduced palatinose (1) A tablet containing a branched-chain amino acid and reduced palatinose.
- the tablet according to any of (1) to (3) above which can be produced by a tablet production method comprising a step of mixing reduced palatinose having a volume average particle diameter of 0.5 to 400 m with a branched-chain amino acid. .
- a method for producing a tablet comprising the step of mixing microcrystalline cellulose having a volume average particle diameter of 20 to 100 m with microcrystalline cellulose and reduced palatinose or a granulated product containing reduced palatinose.
- a method for producing a tablet containing a branched chain amino acid which comprises compression-molding a mixture containing a branched chain amino acid and reduced palatinose by a direct tableting method.
- a method for producing a tablet containing a branched-chain amino acid comprising a step of granulating a mixture containing a branched-chain amino acid and reduced palatinose and a subsequent compression molding step.
- a tablet containing a branched-chain amino acid which can be produced without causing compression molding problems, and a method for producing the same.
- the tablet of the present invention contains a branched-chain amino acid and reduced palatinose, preferably further cellulose, and optionally contains a saccharide, a lubricant, a sweetener, a sour agent, a binder, an antioxidant, a coloring agent, a flavor, It may contain excipients, disintegrants and the like.
- Examples of the branched-chain amino acids in the present invention include palin, leucine, isoleucine, and mixtures of two or three of them.
- the method for producing a branched-chain amino acid is not particularly limited.
- branched-chain amino acids can be purchased, for example, from Kyowa Hakko Kogyo Co., Ltd. or Kyowa Wellness Co., Ltd.
- the proportion occupied by the branched-chain amino acids in the tablet of the present invention is preferably from 10 to 80% by mass, more preferably from 30 to 60% by mass.
- the branched-chain amino acid parin, leucine or isoleucine alone or a mixture of norin, leucine and isoleucine is preferred, and the weight ratio of each component in the mixture is preferably 1: 0.6 to 6: 0.3 to 3.
- Preferred 1: 1 to 3: 0.5 to 1.5 is more preferred.
- leucine and isoleucine are preferably L-forms, which may be any of L-form, D-form and a mixture of L-form and D-form.
- Examples of the reduced palatinose in the present invention include a-D-darcoviranosyl-1,6-sorbitol (GPS), ⁇ -D-darcoviranosyl-1,6, -mantol (GPM), a mixture thereof, and the like. can give.
- GPS a-D-darcoviranosyl-1,6-sorbitol
- GPSM ⁇ -D-darcoviranosyl-1,6, -mantol
- the method for producing reduced palatinose is not particularly limited.
- palatinose is produced by reacting sugar with a glycosyltransferase and then reduced to obtain reduced palatinose.
- the particle size of reduced palatinose used is preferably 0.5 to 400 ⁇ m in terms of volume average particle size as measured by a microscopic method or a sieving method. m is more preferred.
- Reduced palatinose can be purchased, for example, from Shin Mitsui Sugar Co., Ltd. (product name: Palatinit).
- the amount of reduced palatinose relative to the branched-chain amino acid in the tablet of the present invention is preferably 0.1 to 6 parts by mass, more preferably 0.2 to 2 parts by mass, per 1 part by mass of the branched-chain amino acid.
- Examples of the cellulose in the present invention include microcrystalline cellulose.
- the particle diameter of the microcrystalline cellulose used is not particularly limited, but it is about 20 to 100 ⁇ m in volume average particle diameter as measured by a microscopic method or a sieving method. More preferably, it is about 30-60 ⁇ m.
- the particles of the microcrystalline cell mouth preferably have fine voids, which are preferably amorphous rod-shaped particles in order to increase the hardness and disintegration of the tablet.
- the microcrystalline cellulose particles preferably have excellent fluidity in order to increase tablet content uniformity and production speed.
- the method for producing microcrystalline cellulose is not particularly limited.
- Microcrystalline cellulose can also be purchased, for example, from Asahi Kasei Corporation (product name Avicel).
- the proportion occupied by cellulose in the tablet of the present invention is not particularly limited as long as it is within the range of general use in a preparation, but is preferably 0 to 30% by mass.
- the saccharide is not particularly limited as long as it can be used in foods and the like, and includes, for example, monosaccharides, disaccharides, sugar alcohols, oligosaccharides and the like.
- Examples of the monosaccharide include glucose, xylose, galactose, fructose and the like.
- Examples of the disaccharide include trehalose, sucrose, lactose, palatinose and the like.
- Examples of the sugar alcohol include maltitol, erythritol, sorbitol, xylitol and the like.
- Oligosaccharides include, for example, raffinose, inulooligosaccharide (ticolioligosaccharide), nolatinose oligosaccharide, and the like.
- the shape of the saccharide used is not particularly limited, but the particle diameter, which is preferably in the form of microcrystals or fine particles, is determined by measuring the volume when measured by a microscopic method or a sieving method.
- the average particle size is, for example, 1 to 100 / zm, preferably 5 to 80 / zm, more preferably 10 to 60 ⁇ m, and particularly preferably 30 to 50 ⁇ m.
- the proportion occupied by the saccharide in the tablet of the present invention is not particularly limited as long as it is within the range of general use in the preparation.
- the lubricant is not particularly limited as long as it can be used for foods and the like.
- stearic acid such as stearic acid, magnesium stearate, calcium stearate or a metal salt thereof, sucrose fatty acid ester or Glycerin fatty acid esters and hardened fats and oils are exemplified.
- the lubricant may be present only on the surface of the tablet or may be dispersed inside the tablet.
- the proportion of the lubricant in the tablet of the present invention is preferably 0 to 20% by mass, more preferably 0 to 5% by mass, and still more preferably 0 to 1% by mass. Most preferably, it is 0%.
- the tablet of the present invention can be produced without any compression molding obstacle even without substantially containing a lubricant, and also from the viewpoint of the disintegration after taking the tablet and the stability of the components of the tablet.
- a lubricant is not substantially used.
- the sweetener is not particularly limited as long as it can be used in foods and the like, and examples thereof include saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia, thaumatin and the like.
- the proportion occupied by the sweetener in the tablet of the present invention is a general proportion in the preparation. There is no particular limitation as long as it is within the range of the amount used.
- the acidulant is not particularly limited as long as it can be used for foods and the like, and examples thereof include citric acid, tartaric acid, and malic acid.
- the proportion occupied by the acidulant in the tablet of the present invention is not particularly limited as long as it is within the range of general use in the preparation.
- the binder is not particularly limited as long as it can be used for foods and the like, and examples thereof include gelatin and pullulan.
- the proportion occupied by the binder in the tablet of the present invention is not particularly limited as long as it is within the range of general use in the preparation.
- the antioxidant is not particularly limited as long as it can be used for foods and the like, and examples include tocopherol, ascorbic acid, cysteine hydrochloride, and L-ascorbic acid stearic acid ester.
- the proportion occupied by the antioxidant in the tablet of the present invention is not particularly limited as long as it is within the range of general use in the preparation.
- the colorant is not particularly limited as long as it can be used for foods and the like, and examples thereof include Food Yellow No. 5, Food Red No. 2, Food Blue No. 2, carotenoid pigment, tomato pigment and the like.
- the proportion occupied by the colorant in the tablet of the present invention is not particularly limited as long as it is within the range of general use in the preparation.
- the flavor is not particularly limited as long as it can be used for foods and the like, and examples thereof include lemon flavor, lemon lime flavor, grape flavourant flavone, and apulp flavour.
- the proportion of the flavor in the tablet of the present invention is not particularly limited as long as it is within the range of general use in the preparation.
- the excipient is not particularly limited as long as it can be used for foods and the like, and examples thereof include low-substituted hydroxypropylcellulose.
- the proportion occupied by the excipient in the tablet of the present invention is not particularly limited as long as it is within the range of general use in the preparation.
- the disintegrant is not particularly limited as long as it can be used for foods and the like, and includes, for example, corn starch, potato starch and the like.
- the proportion occupied by the disintegrant in the tablet of the present invention is not particularly limited as long as it is within the range of general use in the preparation.
- the tablet of the present invention preferably has a hardness that does not cause, for example, shuffling or collapse.
- Tablet hardness is generally measured by a tablet hardness tester as the breaking strength in the diameter direction of the tablet. However, the value is preferably from 20 to 200N, more preferably from 30N to 150N, even more preferably from 40N to 100N.
- the tablet hardness can be measured by a commercially available tablet breaking strength measuring instrument, for example, Model TH-203CP manufactured by Toyama Sangyo.
- the shape of the tablet of the present invention is not particularly limited, but for example, a round tablet, a triangular tablet, a shot tablet and the like are preferable.
- the size of the tablet of the present invention is not particularly limited, but is preferably, for example, 0.1 to 2 g in mass and 0.3 to 2.0 cm in diameter.
- the tablet of the present invention may be prepared, for example, by mixing each component of the above-mentioned tablet as a powder, mixing a part of the component into a granulated product and then mixing the remaining components,
- the tablet can be produced by a production method including a step of granulating all of the above, and a step of producing a tablet by compression-molding the mixture or granulated substance obtained in the next step. More specifically, a tablet having a desired hardness is also compressed by a production method in which the respective components of the tablet containing a branched-chain amino acid and reduced palatinose are mixed, and the resulting mixture is compression-molded by direct compression.
- the mixture of the constituents can be produced without forming obstacles.
- tablets having a desired hardness can be produced without compression molding obstacles.
- the purity of each branched-chain amino acid is preferably 95% or more, more preferably 98% or more.
- the water content of the branched-chain amino acid is preferably 1% or less, more preferably 0.5% or less.
- the equipment used for compression molding is not particularly limited, and a compressor such as a rotary compression molding machine or a hydraulic press can be used.
- the production method of compression molding by the direct compression method described above is a very simple production method in which each component of the tablet is simply mixed and subjected to compression molding, so that the production method is preferred during the preferred production process. Since water and the like are added to the components, the stability of the components of the tablet is also preferable.
- a tablet having a desired hardness can be compressed even when a lubricant is mixed with each of the above-mentioned mixtures or the above-mentioned granules without substantially using a lubricant.
- a lubricant is not substantially used, since the tablet can be produced without forming obstacles.
- the punch and die of the compression molding machine Apply a trace amount of lubricant in advance and do not contain lubricant in a compression molding machine with a punch and die coated with lubricant!
- the granulation method includes: For example, a wet granulation method using purified water, ethanol, or the like, a dry granulation method, and the like can be given.
- the equipment used for granulation is not particularly limited, and for example, a fluidized bed granulator, a tumbling stirring granulator, an extrusion granulator, and the like can be used.
- the production method of compression molding by the indirect tableting method is preferable in order to make the contents of the branched-chain amino acid and reduced palatinose uniform.
- BCAA (L-parin 10 parts, L-leucine 20 parts, L-isoleucine 10 parts (L-parin and L-isoguchi isin is crushed using a crusher (Model N-2 manufactured by Nara Machinery Co., Ltd. Used and then reduced palatinose (Palatinit PNM-2 (Shin Mitsui Sugar Co., Ltd.), ratatitol (latatitol LC-1 (Niken Kasei Co., Ltd.), maltitol (Mabit 5 (Hayawara Corporation) ) Or lactose (SUPER-TAB (Asahi Kasei Kogyo Co., Ltd.) and microcrystalline cellulose (Avicel FD101 (Asahi Kasei Kogyo Co., Ltd.)) were mixed as shown in Table 1 and mixed well in a polyethylene bag.
- a crusher Model N-2 manufactured by Nara Machinery Co., Ltd. Used and then reduced palatinose (Palatinit PNM-2 (Shin Mits
- tablets with a diameter of 8 mm and 240 mg were compression-molded (single-shot compression molding machine: Kikusui vertical molding machine 6B-2M) Note that all tablet hardness was 59N (hardness measuring device: Fujiwara KHT-20N). The compression molding pressure was adjusted in advance. [Table 1]
- the tablet of the present invention containing a branched-chain amino acid and reduced palatinose is a simple manufacturing method in which a mixture of the respective components of the tablet is compression-molded by a direct compression method, and is substantially free of a lubricant.
- the tablet of the present invention containing a branched-chain amino acid and reduced palatinose is obtained by a simple manufacturing method in which a mixture containing each component of the tablet is directly compression-molded by a tableting method.
- a tableting method it was possible to produce a tablet having a desired hardness without compression molding even without substantially containing a lubricant.
- Fluid bed granulation of a mixture of 1530 g of L-parin (Nara Machinery Co., Ltd., Model M-2 (using 0.5 mm screen), same hereafter) and 1558 g of reduced palatinose using 33.75 g (5% aqueous solution) of pullulan Granulation was performed using a machine (FLO-5, manufactured by Freund Corporation). To 2798 g of the obtained granules, 1200 g of microcrystalline cellulose and 2 g of finely divided nitric acid silicon were added and mixed.
- a mixture of 382.5 g of L-parin, 765 g of L-leucine, 382.5 g of L-isoleucine and 2038.5 g of reduced palatinose was used in a fluidized bed granulator using 29.25 g (5% aqueous solution) of pullulan (FLO-5 manufactured by Freund Corporation). ).
- pullulan FLO-5 manufactured by Freund Corporation.
- the tablet of the present invention containing a branched-chain amino acid and reduced palatinose granulates a mixture containing a branched-chain amino acid and reduced palatinose among the components of the tablet.
- a manufacturing method including a subsequent compression molding step It was possible to produce tablets having a desired hardness without compression molding obstacles even without substantially containing a lubricant.
- the tablet containing a branched-chain amino acid which can be manufactured without causing compression molding trouble, and its manufacturing method can be provided.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05730445.3A EP1738755B1 (en) | 2004-04-14 | 2005-04-14 | Tablet containing branched chain amino acid and process for producing the same |
JP2006512368A JP4847862B2 (ja) | 2004-04-14 | 2005-04-14 | 分岐鎖アミノ酸を含有する錠剤およびその製造方法 |
US11/578,061 US20070224265A1 (en) | 2004-04-14 | 2005-04-14 | Tablet Comprising Branched Chain Amino Acid and Method for Producing the Same |
CN2005800112114A CN1942181B (zh) | 2004-04-14 | 2005-04-14 | 含有支链氨基酸的片剂及其制备方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004118751 | 2004-04-14 | ||
JP2004-118751 | 2004-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005099681A1 true WO2005099681A1 (ja) | 2005-10-27 |
Family
ID=35149749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/007203 WO2005099681A1 (ja) | 2004-04-14 | 2005-04-14 | 分岐鎖アミノ酸を含有する錠剤およびその製造方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070224265A1 (ja) |
EP (1) | EP1738755B1 (ja) |
JP (1) | JP4847862B2 (ja) |
KR (1) | KR20060135022A (ja) |
CN (1) | CN1942181B (ja) |
WO (1) | WO2005099681A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8283327B2 (en) | 2005-03-19 | 2012-10-09 | Kneller Bruce W | Palatinose for enhancing dietary supplement and pharmaceutical delivery |
WO2011043647A1 (en) | 2009-10-09 | 2011-04-14 | N.V. Nutricia | Amino acid composition with improved dispersibility |
US11589603B2 (en) * | 2015-09-11 | 2023-02-28 | Abbott Laboratories | Powdered nutritional product containing branched-chain amino acids and a sugar alcohol |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08256695A (ja) * | 1995-03-22 | 1996-10-08 | Ezaki Glico Co Ltd | 低カロリー性錠菓用顆粒、その製造方法及びその顆粒を使用した錠菓 |
JP2000197454A (ja) * | 1999-01-06 | 2000-07-18 | House Foods Corp | 粉粒体乃至錠剤 |
JP2001089395A (ja) * | 1999-09-16 | 2001-04-03 | Nippon Kagaku Kikai Seizo Kk | 錠剤用賦形剤及び錠剤 |
JP2001258509A (ja) * | 2000-03-16 | 2001-09-25 | Fancl Corp | 錠剤およびその製造方法 |
JP2003221326A (ja) * | 2002-01-25 | 2003-08-05 | Ajinomoto Co Inc | 分岐鎖アミノ酸を含有するチュアブル剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3826946C1 (ja) * | 1988-08-09 | 1990-03-15 | A. Nattermann & Cie Gmbh, 5000 Koeln, De | |
JP4098376B2 (ja) * | 1996-09-05 | 2008-06-11 | ビーエーエスエフ ソシエタス・ヨーロピア | 錠剤特性の優れた水溶性ビタミン組成物およびその製造法 |
NL1012701C2 (nl) * | 1999-07-26 | 2001-01-29 | Sara Lee De Nv | Zoetstof. |
CA2369618C (en) * | 2000-02-17 | 2008-12-23 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyusho | Crystalline mixture solid composition and process for preparation thereof |
EP1444978A1 (en) * | 2001-11-13 | 2004-08-11 | Kyowa Hakko Kogyo Co., Ltd. | Amino acid-containing tablets quickly disintegrating in the oral cavity and process for producing the same |
-
2005
- 2005-04-14 EP EP05730445.3A patent/EP1738755B1/en active Active
- 2005-04-14 WO PCT/JP2005/007203 patent/WO2005099681A1/ja active Application Filing
- 2005-04-14 KR KR1020067021158A patent/KR20060135022A/ko not_active Application Discontinuation
- 2005-04-14 US US11/578,061 patent/US20070224265A1/en not_active Abandoned
- 2005-04-14 JP JP2006512368A patent/JP4847862B2/ja active Active
- 2005-04-14 CN CN2005800112114A patent/CN1942181B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08256695A (ja) * | 1995-03-22 | 1996-10-08 | Ezaki Glico Co Ltd | 低カロリー性錠菓用顆粒、その製造方法及びその顆粒を使用した錠菓 |
JP2000197454A (ja) * | 1999-01-06 | 2000-07-18 | House Foods Corp | 粉粒体乃至錠剤 |
JP2001089395A (ja) * | 1999-09-16 | 2001-04-03 | Nippon Kagaku Kikai Seizo Kk | 錠剤用賦形剤及び錠剤 |
JP2001258509A (ja) * | 2000-03-16 | 2001-09-25 | Fancl Corp | 錠剤およびその製造方法 |
JP2003221326A (ja) * | 2002-01-25 | 2003-08-05 | Ajinomoto Co Inc | 分岐鎖アミノ酸を含有するチュアブル剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1738755A4 * |
Also Published As
Publication number | Publication date |
---|---|
KR20060135022A (ko) | 2006-12-28 |
EP1738755B1 (en) | 2018-05-30 |
US20070224265A1 (en) | 2007-09-27 |
EP1738755A4 (en) | 2012-10-24 |
EP1738755A1 (en) | 2007-01-03 |
JPWO2005099681A1 (ja) | 2007-08-16 |
CN1942181A (zh) | 2007-04-04 |
JP4847862B2 (ja) | 2011-12-28 |
CN1942181B (zh) | 2010-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002238848B2 (en) | Use of a spray-dried powder comprising a sugar alcohol | |
US20040071772A1 (en) | Preparations quickly disintegrating in oral cavity | |
JP4748627B2 (ja) | 賦形剤 | |
KR101203186B1 (ko) | 약물의 맛이 차폐된 경구용 약학 조성물 및 그 제조 방법 | |
JP5342028B2 (ja) | 口腔内崩壊錠 | |
JPWO2008105384A1 (ja) | シトルリン含有錠剤 | |
JP4689468B2 (ja) | 錠剤およびその製造方法 | |
JP2016174616A (ja) | 崩壊性組成物及び易崩壊性圧縮成型物 | |
WO2004078171A1 (ja) | 吸水性アミノ酸含有錠剤 | |
ES2662698T3 (es) | Composiciones de celulosa microcristalina y fosfato de calcio útiles como excipientes farmacéuticos | |
WO2005099681A1 (ja) | 分岐鎖アミノ酸を含有する錠剤およびその製造方法 | |
JP3341768B1 (ja) | 分岐鎖アミノ酸を含有するチュアブル剤 | |
JP2010154769A (ja) | ポリフェノール含有顆粒またはポリフェノール含有チュアブル錠剤およびその製造方法 | |
JP2006335686A (ja) | 直打用エリスリトール・ソルビトール混合顆粒の製造方法 | |
JPWO2016121925A1 (ja) | 機能性物質を高含有する錠剤及びその製造方法 | |
JP3778240B2 (ja) | 不快な味がマスキングされた造粒組成物及びその製造方法 | |
JP5014115B2 (ja) | オルニチン塩酸塩を含有する錠剤 | |
WO2008041740A1 (en) | Glutathione preparation and method for production thereof | |
EP2682104A1 (en) | Orally-disintegrating formulations of dexketoprofen | |
JP2020059660A (ja) | マンニトール造粒物 | |
WO2020092352A1 (en) | Tablets, formulations and methods for low melting point active ingredients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006512368 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11578061 Country of ref document: US Ref document number: 2005730445 Country of ref document: EP Ref document number: 2007224265 Country of ref document: US Ref document number: 1020067021158 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580011211.4 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067021158 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005730445 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11578061 Country of ref document: US |